Cancer medicines
Trastuzumab deruxtecan
Trastuzumab deruxtecan
An antibody-drug conjugate delivering cytotoxic treatment through HER2 targeting.
Sources checked · Introductory guide
On this page
How it works
An ADC linking a HER2 antibody to a topoisomerase I inhibitor. Distinguish it from trastuzumab alone.[3]
Where it is used
Used in selected breast, gastric, lung and other cancers according to HER2 expression or mutation and prior treatment. Eligibility differs by setting.[1]
Key safety points
Interstitial lung disease or pneumonitis can be severe. Report new cough, breathlessness or fever immediately; confirm blood-count and heart monitoring.[2]
Questions for your care team
- How do my HER2 results and prior treatment establish eligibility, and whom do I contact for lung symptoms?
Sources and scope
Source documents are in English.
Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.
- NCI · Fam-Trastuzumab Deruxtecan-nxki (opens in a new tab)
- MedlinePlus · Fam-Trastuzumab Deruxtecan-nxki (opens in a new tab)
- NCI Drug Dictionary · Fam-Trastuzumab Deruxtecan-nxki (opens in a new tab)
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.